Strides Arcolab standalone Q4 net swings into black

Total income from operations up 5% to Rs 270 cr; firm has not disclosed consolidated numbers

Bengaluru-based drug maker Strides Arcolab today reported a standalone net profit of Rs 69.66 crore for the quarter-ended March 31, 2015. The company had posted a net loss of Rs 48.26 crore for the corresponding period of the previous fiscal, the company said in a filing on the BSE.

The company's standalone total income from operations rose 5.18 per cent to Rs 270.03 crore during the quarter under consideration. The company has not disclosed consolidated numbers for the quarter.

Commenting on the results, Strides Arcolab Founder and Group CEO Arun Kumar said: "The quality of business and profitability has been hallmark of our FY15 performance. The merger with Shasun Pharma and re-entry into the Australian market will make us a fully-integrated global pharmaceutical company with size and scale."

Meanwhile, Strides has announced that its board has recommended a dividend of Rs 3 per share for year-ended March 31, 2015. Strides Arcolab shares ended up .49 per cent at Rs 1,193.70 on the BSE.